Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Health challenges in the Golden Land

Steve Finch
CMAJ March 05, 2013 185 (4) E179-E180; DOI: https://doi.org/10.1503/cmaj.109-4368
Steve Finch
Yangon, Myanmar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Emerging from the shadows of five decades of military rule, the nation once known as the “Jewel of Asia” is beset by an array of less than illustrious health challenges, including high rates of beri-beri, malaria, HIV/AIDS and tuberculosis (TB). And while Myanmar is initiating reforms at a pace that United States President Barack Obama called “remarkable,” those challenges remain acute against a backdrop of widespread malnutrition, especially in rural areas.

It is the only country on the planet where the easily treatable, thiamine-deficiency disease, beri-beri, is still a leading cause of child mortality.

Myanmar is also the country that has been identified as the main Asia–Pacific threat in the global fight to contain malaria. A recent study has shown a rise in cases of drug-resistant strains on the Myanmar–Thai border, scene of the world’s longest-running civil war between government forces and ethnic Kayin, where access is difficult and medical facilities almost nonexistent (Malaria Journal 2012;11:290).

Papers presented at a regional malaria conference in Sydney, Australia in October 2012, identified poor surveillance, presumptive diagnoses and a health sector that too often issues poor quality, single-drug treatments as obstacles to the treatment of malaria (http://malaria2012conference.com/cms/wp-content/uploads/2012/10/Malaria-2012-Issues-paper-No-3.pdf). The Golden Land was responsible for 70% of malaria deaths in the Mekong region in 2010.

“Myanmar has received very little support to contain the spread of resistance and is potentially a route for resistant parasites to spread to other regions,” according to a paper issued in Sydney (http://malaria2012conference.com/cms/wp-content/uploads/2012/10/Malaria-2012-Issues-paper-No-4.pdf).

But the nation is aiming to ramp up testing and switch to artemisinin-based combination therapy, says Dr. Saw Lwin, deputy director general of the Myanmar Department of Health. With still only 65% of malaria cases confirmed and just 10% of the country’s roughly 49 million people, living in a 676 578 km2 area, covered by durable, insecticide-sprayed mosquito nets, “all implementing partners are scaling up case-finding activities and distribution of … nets,” he says.

Figure

In some areas of Myanmar, access to health facilities is all but nonexistent.

Image courtesy of © 2013 Thinkstock

Myanmar’s HIV/AIDS epidemic is similarly urgent. Although incidence peaked around the turn of the millennium and is falling, that’s primarily due to a woefully high mortality rate. By 2013, fewer than 200 000 people in Myanmar will be HIV-positive, versus about 210 000 a year ago. But that’s due to the deaths of an estimated 18 000 people, the majority of whom died from AIDS-related TB. Over the same period, roughly 8300 new cases of AIDS among people over the age of 15 were diagnosed, according to a working group comprised of United Nations and Myanmar Department of Health officials (www.hivinfo4mm.org/wordpress/wp-content/uploads/myanmar-hiv-estimates1.pdf).

The high AIDS mortality rate is strictly a function of the low provision rate for antiretrovirals. Only about 40 000 of the estimated 125 000 people in need of treatment in 2011 received antiretrovirals, according to UNAIDS, a lower percentage than Mozambique and about the same as neighbouring India (www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf).

“This practically means that two out of three people that needed HIV/AIDS treatment were not receiving it,” Peter Paul de Groote, head of the Dutch chapter of the international medical relief agency Médecins Sans Frontières (MSF) in Myanmar, said at the opening of a new TB/HIV outpatient centre in Yangon in December 2012.

Duncan Bell, head of mission at the Swiss chapter of MSF, says that although the widely accepted time to start anti-retroviral treatment is after a CD4 count falls to 350, that does not happen often in Myanmar.

Treatment did not begin for the roughly 20 000 people that MSF provided antiretrovirals to in 2011 until they had CD4 counts of 150 or lower, Bell says. “This is simply due to a lack of funding.”

Myanmar ranks close to the bottom among the 22 TB high-burden countries on testing labs per capita, according to the World Health Organization. In 2011, Myanmar administered HIV tests to just 3.1% of TB patients, all of whom were started on cotrimoxazole preventive therapy but only 80% of whom received antiretrovirals.

But Bell says the problems extend well beyond the availability of financial resources and points to headaches that resulted when MSF sought to open one of four new TB/HIV centres in Yangon. Stigmatization meant landlords were unwilling to rent out land or buildings for the clinic, forcing Minister of Health Dr. Pe Thet Khin to intervene and allow MSF to establish it on the grounds of a state hospital. Even then, managers tried to block the move.

It was eventually opened and is now the first such facility located within a Myanmar ministry facility, says Bell. It’s a sign of capacity problems and a lack of cooperation that stems from decades of military rule, he notes, adding that such issues suggest Myanmar’s health system will take substantial time to improve. “Yes, there is reform but let’s not get euphoric yet.”

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 185 (4)
CMAJ
Vol. 185, Issue 4
5 Mar 2013
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Health challenges in the Golden Land
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Health challenges in the Golden Land
Steve Finch
CMAJ Mar 2013, 185 (4) E179-E180; DOI: 10.1503/cmaj.109-4368

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Health challenges in the Golden Land
Steve Finch
CMAJ Mar 2013, 185 (4) E179-E180; DOI: 10.1503/cmaj.109-4368
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Is one-way masking enough?
  • XE, XD & XF: what to know about the Omicron hybrid variants
  • 5 infectious disease topics to watch
Show more News

Similar Articles

Collections

  • Topics
    • Global health

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire